Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Free Cash Flow (2016 - 2025)

Neuroone Medical Technologies' Free Cash Flow history spans 14 years, with the latest figure at -$3.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 1818.97% year-over-year to -$3.2 million; the TTM value through Dec 2025 reached -$6.2 million, up 12.52%, while the annual FY2025 figure was -$2.9 million, 73.78% up from the prior year.
  • Free Cash Flow reached -$3.2 million in Q4 2025 per NMTC's latest filing, down from -$1.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $951635.0 in Q3 2022 to a low of -$3.8 million in Q4 2023.
  • Average Free Cash Flow over 5 years is -$2.2 million, with a median of -$2.5 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: skyrocketed 146.1% in 2022, then crashed 1818.97% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$2.7 million in 2021, then fell by 27.85% to -$3.5 million in 2022, then fell by 9.78% to -$3.8 million in 2023, then surged by 104.77% to $183633.0 in 2024, then plummeted by 1818.97% to -$3.2 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Free Cash Flow are -$3.2 million (Q4 2025), -$1.5 million (Q3 2025), and -$1.5 million (Q2 2025).